Ucb S.a Stock Earnings Reports

UCB reported a very strong H1 2026: total net sales of EUR 4.1bn (up ~23% reported / ~28% at constant rates), led by five growth drivers that now represent >50% of revenue. BIMZELX is the clear engine of momentum (H1 net sales ~EUR 1.5bn, rapid uptake across psoriasis, HS and rheumatology), the company reiterated a revised peak-sales ambition for BIMZELX of at least EUR 7bn and highlighted four head-to-head superiority trials including recent BE BOLD versus SKYRIZI in PsA. Management upgraded full-year guidance (revenue growth now expected low‑teens to mid‑teens CER; adjusted EBITDA growth mid‑teens to low‑20s CER) and reported adjusted EBITDA of EUR 1.7bn in H1 (margin 40.7%). Key pipeline and BD updates: acquisitions of Candid Therapeutics (BCMA T‑cell engager cizutamig) and Neurona (allogeneic interneuron cell therapy rezanecel) to expand into potentially transformative modalities, plus IMIDomics; bepranemab will advance into a confirmatory Phase II (targeting a TAU‑low subpopulation); galvokimig recruitment is accelerating and respiratory plans are underway. Financial/operational caveats: BRIVIACT generic entry is impacting H2 (U.S. LOE Feb; Europe expected Aug), gross-to-net phasing benefits helped H1, and newly secured access contracts (notably a large PBM first‑line placement effective June 1) are expected to create near‑term net price pressure while driving longer‑term volume. Management signals continued disciplined R&D (~25% of sales mid‑term), focused lifecycle work (pediatrics, additional indications) and selective M&A, but notes integration and phasing considerations. Overall: strong top‑line momentum, margin expansion in H1, upgraded guidance, meaningful inorganic moves to broaden platform and potentially deliver durable, high‑value growth — balanced against LOE and pricing/access dynamics that will influence H2 progression.